  Oncolytic virotherapy is an experimental cancer treatment that uses
genetically engineered viruses to target and kill cancer cells. One major
limitation of this treatment is that virus particles are rapidly cleared by the
immune system, preventing them from arriving at the tumour site. To improve
virus survival and infectivity modified virus particles with the polymer
polyethylene glycol (PEG) and the monoclonal antibody herceptin. While PEG
modification appeared to improve plasma retention and initial infectivity it
also increased the virus particle arrival time. We derive a mathematical model
that describes the interaction between tumour cells and an oncolytic virus. We
tune our model to represent the experimental data by Kim et al. (2011) and
obtain optimised parameters. Our model provides a platform from which
predictions may be made about the response of cancer growth to other treatment
protocols beyond those in the experiments. Through model simulations we find
that the treatment protocol affects the outcome dramatically. We quantify the
effects of dosage strategy as a function of tumour cell replication and tumour
carrying capacity on the outcome of oncolytic virotherapy as a treatment. The
relative significance of the modification of the virus and the crucial role it
plays in optimising treatment efficacy is explored.
